| Name | Title | Contact Details |
|---|
ACGT DNA Technologies is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Microbion is a clinical stage biopharmaceutical company. Microbion is developing MBN-101 as the first product in the bismuth-thiol class for the treatment of resistant and difficult to treat infections. MBN-101 has broad spectrum, anti-bacterial efficacy against a broad range of pathogens, including multiple priority pathogens or “superbugs”. In addition to anti-bacterial efficacy, MBN-101 also has highly advantageous and product-differentiating capability to prevent and eradicate microbial biofilms. The dual action from this first in class product provides a novel clinical approach to treating infections. Their effectiveness against MRSA, MDR TB, CRE, VRE, and other antibiotic resistant pathogens highlights their potential to provide solutions to the dramatic and alarming increase in global antibiotic resistance.
FluidForm Bio™ is creating living human tissue for better treatment of disease. Our patented FRESH™ technology is a revolutionary platform designed to build tissue using cells, proteins, and nothing else. Through partnerships with top life science companies, our technology has been validated to produce the highest quality tissue in a variety of applications. We deliver human tissue that is indistinguishable from the real thing by integrating breakthrough innovations in 3D printing, computational and synthetic biology, AI, and advanced materials science. Our living tissue will offer therapies to countless patients who deserve better treatment options.
CELLINK is the first bioink company revolutionizing bioprinting. Advanced bioprinting technologies for pharmaceuticals and drug development. CELLINK is pioneering cell cultivation systems through bioprinting, analysis and liquid handling or bioprocessing.
Marengo Therapeutics is pioneering an entirely new way to activate the body`s own immune system to mount a rapid, effective, and durable response against cancer. Our unique therapeutic platform selectively boosts T cells, turbocharging potent anti-tumor activity and promoting long-term immunity to keep cancer at bay.